The trial realized the two its primary endpoints, with semaglutide 2.four mg demonstrating statistically considerable and exceptional improvements in liver fibrosis with no worsening of steatohepatitis, in addition to resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH compared to placebo.oneAssuming the above ment